Certainly!

Below is the revised and more detailed organization of the antihypertensive and
antianginal drugs based on your original content. Each drug has its own Mechanism of
Action, Clinical Uses, Side Effects, and Contraindications, while ensuring that all
information from the original chart is included.

Antihypertensive Medications

Diuretics

Mechanism of
Drug Clinical Uses Side Effects Contraindications
Action

Inhibit Na+/Cl−
Mild hypertension, Hypokalemia, Severe renal
Thiazide symporter in distal
adjunct to other hyperuricemia, impairment,
Diuretics convoluted tubule,
drugs hyperglycemia anuria
reducing sodium
reabsorption
Inhibit

Na+/K+/2Cl− Severe Hypokalemia, Anuria, severe

Loop
hypertension, CHF, ototoxicity, electrolyte
Diuretics symporter in loop
renal failure dehydration imbalance
of Henle, potent
diuresis
Block Na+
channels
Potassium- (amiloride, Prevent Hyperkalemia,
Hyperkalemia,
Sparing triamterene) or hypokalemia, CHF, gynecomastia
renal failure
Diuretics aldosterone hyperaldosteronism (spironolactone)
receptor
(spironolactone)

ACE Inhibitors
 Drug Mechanism of Action Clinical Uses Side Effects Contraindications
Block conversion of
angiotensin I to II, Dry cough, Pregnancy, history of
Hypertension,
Enalapril reducing angioedema, angioedema, renal
CHF, post-MI
vasoconstriction and hyperkalemia artery stenosis
aldosterone secretion
Block conversion of
angiotensin I to II, Dry cough, Pregnancy, history of
Hypertension,
Lisinopril reducing angioedema, angioedema, renal
CHF, post-MI
vasoconstriction and hyperkalemia artery stenosis
aldosterone secretion
Block conversion of
angiotensin I to II, Dry cough, Pregnancy, history of
Hypertension,
Ramipril reducing angioedema, angioedema, renal
CHF, post-MI
vasoconstriction and hyperkalemia artery stenosis
aldosterone secretion

Angiotensin II Receptor Blockers (ARBs)

Mechanism of
Drug Clinical Uses Side Effects Contraindications
Action
Block AT1
receptors, Hypertension, Hyperkalemia,
Pregnancy, bilateral
Losartan preventing CHF, diabetic dizziness,
renal artery stenosis
angiotensin II nephropathy hypotension
effects
Block AT1
receptors, Hypertension, Hyperkalemia,
Pregnancy, bilateral
Valsartan preventing CHF, diabetic dizziness,
renal artery stenosis
angiotensin II nephropathy hypotension
effects

Calcium Channel Blockers (CCBs)

 Mechanism of
Drug Clinical Uses Side Effects Contraindications
Action
Block L-type Ca2+ Dizziness,
Hypertension, Severe
channels, reducing hypotension,
Amlodipine angina, coronary hypotension, heart
vascular and reflex
artery disease block
cardiac contractility tachycardia
Block L-type Ca2+
Hypertension, Dizziness, Severe
channels, reducing
Diltiazem angina, bradycardia, hypotension, heart
vascular and
arrhythmias hypotension block
cardiac contractility
Block L-type Ca2+ Dizziness,
Hypertension, Severe
channels, reducing constipation,
Verapamil angina, hypotension, heart
vascular and bradycardia,
arrhythmias block
cardiac contractility hypotension

Beta-Blockers

Mechanism of
Drug Clinical Uses Side Effects Contraindications
Action
Block β1
receptors, Bradycardia, Asthma, severe
Hypertension,
Atenolol reducing heart fatigue, dizziness, bradycardia, heart
angina, post-MI
rate and bronchospasm block
contractility
Block β1
receptors, Bradycardia, Asthma, severe
Hypertension,
Metoprolol reducing heart fatigue, dizziness, bradycardia, heart
angina, post-MI
rate and bronchospasm block
contractility
Block β1/β2
Bradycardia,
receptors, Hypertension, Asthma, severe
fatigue,
Propranolol reducing heart angina, post-MI, bradycardia, heart
bronchospasm
rate and arrhythmias block
(non-selective)
contractility

Alpha-Blockers
 Mechanism of
Drug Clinical Uses Side Effects Contraindications
Action
Orthostatic
Block α1
Hypertension, hypotension, Hypotension, heart
Doxazosin receptors, leading
BPH dizziness, reflex failure
to vasodilation
tachycardia
Orthostatic
Block α1
Hypertension, hypotension, Hypotension, heart
Prazosin receptors, leading
BPH dizziness, reflex failure
to vasodilation
tachycardia

Antianginal Medications

Organic Nitrates

Clinical
Drug Mechanism of Action Side Effects Contraindications
Uses
Release nitric oxide Headache,
Angina, Hypotension, recent
→ activates guanylyl hypotension,
Nitroglycerin acute MI, use of PDE5
cyclase → ↑ cGMP reflex
CHF inhibitors
→ vasodilation tachycardia
Release nitric oxide Headache,
Hypotension, recent
Isosorbide → activates guanylyl Angina, hypotension,
use of PDE5
Dinitrate cyclase → ↑ cGMP MI, CHF reflex
inhibitors
→ vasodilation tachycardia
Release nitric oxide Headache,
Hypotension, recent
Isosorbide → activates guanylyl Angina, hypotension,
use of PDE5
Mononitrate cyclase → ↑ cGMP MI, CHF reflex
inhibitors
→ vasodilation tachycardia

Centrally Acting Agents

 Mechanism of
Drug Clinical Uses Side Effects Contraindications
Action
Stimulates α2
Hypertension, Sedation, dry Depression,
receptors, reducing
Clonidine opioid mouth, rebound bradycardia,
sympathetic
withdrawal hypertension hypotension
outflow
Stimulates α2
Hypertension, Sedation, dry
receptors, reducing Liver disease,
Methyldopa especially in mouth, rebound
sympathetic depression
pregnancy hypertension
outflow

Vasodilators

Mechanism of
Drug Clinical Uses Side Effects Contraindications
Action
Direct arterial
Reflex
relaxation, Coronary artery
Hypertension, tachycardia,
Hydralazine reducing systemic disease, mitral valve
heart failure lupus-like
vascular disease
symptoms
resistance
Direct arterial
Reflex
relaxation, Severe Pheochromocytoma,
tachycardia,
Minoxidil reducing systemic hypertension, coronary artery
fluid retention,
vascular heart failure disease
hypertrichosis
resistance
Donates nitric
oxide → activates Reflex
Hypertensive Pregnancy, renal
Nitroprusside guanylyl cyclase tachycardia,
emergencies failure
→ ↑ cGMP → cyanide toxicity
vasodilation

This version should comprehensively include all the drugs, their mechanisms, clinical uses,
side effects, and contraindications, as per the original content you provided. Let me know
if you need any further modifications or clarifications!
 [Anti Heart Failure]

Here’s the merged table combining the information from both tables:

Mechanism of
Drug Clinical Uses Side Effects Contraindications
Action
A β1-agonist
that increases
Tachycardia, Should be
cardiac Short-term
arrhythmias, and limited in long-
contractility and management of
Dobutamine increased mortality term use for
stroke volume severe heart
with prolonged severe heart
without causing failure.
use. failure.
much
vasodilation.
Phosphodiesterase
(PDE) type 3
inhibitor. Acute heart
Not
Increases cAMP failure,
Thrombocytopenia, recommended for
in cardiac inotropic
ventricular long-term use in
myocytes to support for
Milrinone arrhythmias, severe heart
enhance patients
increased mortality failure due to
contractility and awaiting
with long-term use. increased
in vascular cardiac
mortality.
smooth muscle to transplantation.
cause
vasodilation.
Inhibit the
conversion of
angiotensin I to Treatment of Hypotension,
Contraindicated
angiotensin II, heart failure, cough (in some
in pregnancy and
ACE Inhibitors reducing hypertension, cases),
bilateral renal
vasoconstriction, and diabetic hyperkalemia, and
artery stenosis.
aldosterone nephropathy. renal impairment.
secretion, and
fluid retention.
Block the AT1 Used in heart Dizziness,
Contraindicated
ARBs receptor for failure and hyperkalemia,
in pregnancy.
angiotensin II, hypertension, hypotension.
 Mechanism of
Drug Clinical Uses Side Effects Contraindications
Action
preventing its especially for
vasoconstrictive patients
effects. intolerant of
ACE
inhibitors.
Recombinant
human B-type
natriuretic peptide Acute Contraindicated
that promotes decompensated in patients with
Hypotension (most
vasodilation heart failure low cardiac
cases
Nesiritide through increasedwith dyspnea output and
asymptomatic),
cGMP at rest or with systolic blood
renal impairment.
production, minimal pressure under
reducing cardiac activity. 100 mmHg.
preload and
afterload.
Neprilysin
inhibitor, Combined with
Contraindicated
increases levels of valsartan
in patients with a
natriuretic (Entresto) for
Hyperkalemia, history of
peptides and treatment of
Sacubitril hypotension, angioedema
bradykinin, heart failure
angioedema. related to ACE
promoting with reduced
inhibitors,
vasodilation and ejection
pregnancy.
reducing sodium fraction.
retention.
Hydralazine
causes arterial
Heart failure,
vasodilation,
especially in Hypotension,
Hydralazine & while isosorbide
patients who dizziness, Contraindicated
Isosorbide dinitrate induces
cannot tolerate headache, in hypotension.
Dinitrate venous dilation.
ACE inhibitors tachycardia.
Combined, they
or ARBs.
reduce preload
and afterload,
 Mechanism of
Drug Clinical Uses Side Effects Contraindications
Action
improving cardiac
output.
Block β-
adrenergic
receptors,
reducing heart
Management Contraindicated
rate and Bradycardia,
β-Blockers of chronic in patients with
contractility, dizziness,
(Carvedilol, heart failure, severe
which in turn worsening heart
Metoprolol, particularly bradycardia,
decreases failure,
Bisoprolol) systolic heart block, or
myocardial hypotension.
dysfunction. hypotension.
oxygen demand
and reduces
cardiac
remodeling.
Competitively
bind to
mineralocorticoid
receptors in the Severe heart
Hyperkalemia, Contraindicated
Aldosterone kidneys, failure,
gynecomastia in patients with
Antagonists preventing prevention of
(spironolactone), hyperkalemia or
(Spironolactone, aldosterone’s mortality in
impotence renal
Eplerenone) action, which systolic heart
(spironolactone). insufficiency.
reduces sodium failure.
retention and
increases
potassium levels.
Increase urine
Acute heart
output by Electrolyte
failure, chronic Contraindicated
inhibiting sodium imbalances (e.g.,
Diuretics (Loop heart failure in patients with
reabsorption in hypokalemia,
Diuretics, for symptom renal failure or
the kidneys, hyponatremia),
Thiazides) relief severe electrolyte
reducing fluid dehydration,
(dyspnea, imbalances.
overload in heart hypotension.
edema).
failure.
This table merges both the detailed pharmacological information on the mechanisms, uses,
side effects, and contraindications with the previously structured data. Let me know if
you'd like any further adjustments!

-----------------------------------------------------[Diuretics]----------------------------------------------
Drug Mechanism Contraindicati
Drug Name(s) Clinical Uses Side Effects
Class of Action ons
Inhibit
Hypokalemia
Na+/Cl− Hypertension,
,
edema,
Hydrochlorothiaz symporter in hyperuricemi Severe renal
Thiazide nephrogenic
ide, the distal a, failure, sulfa
Diuretics diabetes
Chlorthalidone tubule, hyperglycemi allergy
insipidus,
leading to a, metabolic
hypercalciuria
natriuresis alkalosis
and diuresis.
Inhibit
Na+/K+/2Cl

− symporter

in the Hypokalemia Severe

ascending Heart failure, , ototoxicity, electrolyte
Furosemide,
limb of the renal failure, dehydration, depletion,
Loop Bumetanide,
loop of pulmonary metabolic sulfa allergy
Diuretics Torsemide,
Henle, edema, alkalosis, (except
Ethacrynic Acid
increasing hypercalcemia nephrotoxicit ethacrynic
Na+, K+, y acid)

Cl−, Ca2+,

and Mg2+
excretion.
Spironolacto
ne and Prevent Hyperkalemi
Spironolactone,
Potassium eplerenone: hypokalemia, a, Hyperkalemia,
Eplerenone,
-Sparing Aldosterone heart failure, gynecomastia renal
Amiloride,
Diuretics receptor hyperaldosteroni (spironolacto insufficiency
Triamterene
antagonists; sm ne)
Amiloride
 Drug Mechanism Contraindicati
Drug Name(s) Clinical Uses Side Effects
Class of Action ons
and
triamterene:
Block Na+
channels in
the
collecting
duct.
Increase
osmotic
pressure in
plasma,
attracting
Excessive
water from
Cerebral edema, plasma Heart failure,
interstitial
acute glaucoma, volume severe
Osmotic Mannitol, and
acute renal expansion, dehydration,
Diuretics Glycerol transcellular
failure, toxin heart failure, active cranial
fluids.
elimination pulmonary hemorrhage
Mannitol
congestion
also inhibits
water
reabsorption
in renal
tubules.
Inhibit
carbonic
anhydrase,
reducing Glaucoma,
Metabolic
Carbonic sodium high-altitude Severe hepatic
acidosis,
Anhydras Acetazolamide, bicarbonate sickness, or renal
hypokalemia,
e Dorzolamide reabsorption metabolic dysfunction,
paresthesia,
Inhibitors in the alkalosis, sulfa allergy
renal stones
proximal epilepsy
tubule,
leading to
metabolic
 Drug Mechanism Contraindicati
Drug Name(s) Clinical Uses Side Effects
Class of Action ons
acidosis and
diuresis.
Block
vasopressin
V2
receptors,
ADH inhibiting Hypovolemic
Hypernatremi
Antagonis aquaporin Euvolemic and hyponatremia,
Conivaptan, a, infusion
ts insertion in hypervolemic CYP3A4
Tolvaptan site reactions
(Aquareti the hyponatremia inhibitor
(conivaptan)
cs) collecting interactions
ducts,
increasing
free water
excretion.

Inotrope（變力性藥物） vs. Chronotrope（變時性藥物）

這兩類藥物影響心臟的不同功能：

臨床
類別 作用 影響 代表性藥物
應用
治療 正性：Dobutamine,
正性 inotrope 心臟 Digoxin, Epinephrine
增加心肌收縮 衰 負性：β-blockers
Inotrope（變 改變心肌收縮力
力，負性 竭、 (e.g., Metoprolol),
力性藥物） （contractility）
inotrope 減少心 心源 Calcium channel
肌收縮力 性休 blockers (e.g.,
克 Verapamil)
正性 治療
正性：Atropine,
Chronotrope 改變心跳速率 chronotrope 增 心動
Epinephrine 負性：β-
（變時性藥 （heart rate, 加心跳速率，負 過緩
blockers (e.g.,
物） HR） 性 chronotrope 或心
Propranolol), Digoxin
降低心跳速率 動過
 臨床
類別 作用 影響 代表性藥物
應用
速

簡單記憶法：

• Ino-（力）：影響心肌收縮力
• Chrono-（時間）：影響心跳速率

//

Here's the combined chart of anticoagulant and antiplatelet drugs, organized by their
mechanism of action, clinical uses, side effects, and contraindications:

Mechanism of Contraindication
Drug Clinical Uses Side Effects
Action s
Treatment of acute
Inactivates
thromboembolic Bleeding,
thrombin and Active bleeding,
Heparin disorders (DVT, heparin-induced
factor Xa by thrombocytopeni
(Unfractionate PE), prevention of thrombocytopeni
binding to a, history of HIT,
d) clotting in arterial a (HIT),
antithrombin III hypersensitivity.
and heart surgery, hyperkalemia.
(AT-III).
dialysis, etc.
Inactivates
Prophylaxis and
factor Xa more Bleeding, Active bleeding,
treatment of DVT,
Enoxaparin selectively, less thrombocytopeni hypersensitivity
PE, acute coronary
(LMWH) effect on a, hematoma, to LMWH or
syndrome, and after
thrombin than local irritation. heparin.
surgery.
heparin.
Prevention of
Similar to
venous
enoxaparin, Bleeding,
Dalteparin thromboembolism Active bleeding,
selectively thrombocytopeni
(LMWH) post-surgery, hypersensitivity.
inhibits factor a, bruising.
unstable angina,
Xa.
ACS.
Selectively Active bleeding,
Prophylaxis for Bleeding,
Fondaparinux inhibits factor severe renal
DVT in hip/knee anemia,
Xa. impairment.
 Mechanism of Contraindication
Drug Clinical Uses Side Effects
Action s
surgery, treatment thrombocytopeni
of PE and DVT. a.
Direct thrombin Prevention of
inhibitor, binds thrombosis in
Bleeding, pain at Active bleeding,
Bivalirudin to thrombin unstable angina,
injection site. hypersensitivity.
without need for MI, and during
antithrombin III. PCI.
Treatment of
Bleeding,
Direct thrombin thrombosis in Active bleeding,
Argatroban hypotension,
inhibitor. patients with HIT, hypersensitivity.
bradycardia.
PCI for MI.
Direct thrombin Stroke prevention
Bleeding
inhibitor, binds in nonvalvular Active bleeding,
(especially GI),
thrombin’s atrial fibrillation, severe renal
Dabigatran dyspepsia,
active site to DVT and PE impairment,
gastritis,
prevent fibrin prevention/treatmen hypersensitivity.
headache.
formation. t, hip surgery.
Stroke prevention
Inhibits factor in atrial fibrillation, Active bleeding,
Bleeding,
Xa activity by DVT/PE prevention hypersensitivity,
Apixaban elevated liver
binding to the and treatment, severe hepatic
enzymes.
active site. postoperative DVT impairment.
prevention.
Active bleeding,
Stroke prevention severe renal
Bleeding, liver
Inhibits factor in atrial fibrillation, impairment,
Edoxaban enzyme
Xa. DVT/PE prevention creatinine
elevation.
and treatment. clearance >95
mL/min in AF.
Stroke prevention
Active bleeding,
in atrial fibrillation,
Bleeding, liver hypersensitivity,
Inhibits factor DVT/PE prevention
Rivaroxaban enzyme severe
Xa. and treatment,
elevation. renal/hepatic
postoperative DVT
impairment.
prevention.
 Mechanism of Contraindication
Drug Clinical Uses Side Effects
Action s
Irreversibly
inhibits
Prevention of
cyclooxygenase
arterial
(COX-1), Active GI
thromboembolism, Gastrointestinal
reducing bleeding, peptic
stroke, MI, bleeding,
Aspirin thromboxane A2 ulcer disease,
secondary dyspepsia,
production, hypersensitivity
prevention after MI ulcers.
leading to to NSAIDs.
or stroke, treatment
inhibition of
of acute MI.
platelet
aggregation.
Irreversibly
inhibits platelet Prevention of
Active bleeding,
P2Y12 arterial Bleeding,
hypersensitivity,
Clopidogrel receptors, thromboembolism thrombocytopeni
severe hepatic
reducing ADP- in MI, stroke, ACS, a, rash.
impairment.
induced platelet PCI.
aggregation.
Irreversibly
ACS, especially in Bleeding, Active bleeding,
inhibits platelet
Prasugrel patients undergoing hypertension, history of stroke,
P2Y12
PCI. hyperlipidemia. hypersensitivity.
receptors.
Bleeding, Active bleeding,
Reversibly
dyspnea, history of
inhibits platelet ACS, adjunct to
Ticagrelor bradycardia, intracranial
P2Y12 PCI.
elevated serum hemorrhage,
receptors.
uric acid. hypersensitivity.
Reversibly Adjunct to PCI, for
inhibits platelet patients who need Bleeding, Active bleeding,
Cangrelor
P2Y12 temporary platelet hypotension. hypersensitivity.
receptors. inhibition.
Binds to platelet
Bleeding, Active bleeding,
GP IIb/IIIa Acute coronary
Abciximab thrombocytopeni thrombocytopeni
receptors, syndrome, PCI.
a, bradycardia. a, history of
preventing
 Mechanism of Contraindication
Drug Clinical Uses Side Effects
Action s
fibrinogen bleeding
binding and disorders.
platelet
aggregation.
Inhibits platelet
aggregation by Active bleeding,
preventing the Bleeding, thrombocytopeni
Eptifibatide binding of ACS, PCI. thrombocytopeni a, history of
fibrinogen to GP a, hypotension. bleeding
IIb/IIIa disorders.
receptors.
Inhibits platelet Active bleeding,
aggregation by Bleeding, thrombocytopeni
Tirofiban blocking GP ACS, PCI. thrombocytopeni a, history of
IIb/IIIa a, hypotension. bleeding
receptors. disorders.
Blocks PAR-1
Prevention of
receptors on Active bleeding,
atherothrombotic
platelets, Bleeding, history of stroke
events in patients
Vorapaxar preventing anemia, or TIA, severe
with history of MI
thrombin- headache. hepatic
or peripheral
induced platelet impairment.
arterial disease.
aggregation.
Inhibits platelet
aggregation by Stroke prevention
increasing (with aspirin),
Headache,
platelet cAMP coronary Active bleeding,
Dipyridamole dizziness, GI
levels via vasodilator in hypersensitivity.
upset, bleeding.
blocking myocardial
adenosine perfusion imaging.
uptake.
Inhibits Headache,
Heart failure,
phosphodiesteras Intermittent diarrhea,
Cilostazol active bleeding,
e type 3 (PDE3), claudication. palpitations,
hypersensitivity.
increasing bleeding.
 Mechanism of Contraindication
Drug Clinical Uses Side Effects
Action s
cAMP levels
and reducing
platelet
aggregation.

This chart combines both the mechanisms and detailed clinical information for
anticoagulant and antiplatelet drugs. Let me know if you'd like any changes or further
elaboration!

//
最終凝血

Here is the combined chart with both sets of information, merging the pharmacokinetics,
mechanisms of action, clinical uses, side effects, and contraindications:

Mechanis
Pharmacokinet Contraindicati
Drug Name m of Clinical Uses Side Effects
ics ons
Action
Prevention of
thrombosis and
Active
MI in ACS,
bleeding,
Oral prodrug, Inhibits secondary
Bleeding, risk hypersensitivit
activated by ADP at stroke
Clopidogrel of bleeding y to
P450 enzymes P2Y12 prevention,
with aspirin clopidogrel,
(CYP2C19) receptor thrombosis
severe hepatic
prevention in
impairment
various
conditions
Active
Prevention of
Oral prodrug, Inhibits bleeding,
thrombosis and Bleeding, risk
activated by ADP at hypersensitivit
Prasugrel MI in ACS, of bleeding
CYP3A4 and P2Y12 y to prasugrel,
often used with with aspirin
CYP2B6 receptor severe hepatic
aspirin
impairment
Oral, does not Inhibits Prevention of Dyspnea, Active
Ticagrelor
require ADP at thrombosis and bleeding bleeding,
 Mechanis
Pharmacokinet Contraindicati
Drug Name m of Clinical Uses Side Effects
ics ons
Action
activation, P2Y12 MI in ACS, hypersensitivit
more rapid receptor superior for y to ticagrelor,
onset of action stent severe hepatic
thrombosis impairment
prevention
Intravenous,
no prior Inhibits Adjunct to PCI
Bleeding, risk Hypersensitivit
administration ADP at to reduce
Cangrelor of bleeding y to cangrelor,
of P2Y12 P2Y12 thrombotic
with aspirin active bleeding
blocker receptor events
required
Binds
tightly to Used during
Bleeding, Active
Intravenous, GP-2b/3a PCI to prevent
thrombocytopen bleeding,
Abciximab monoclonal receptors, platelet
ia, hypotension, hypersensitivit
antibody preventing aggregation and
bradycardia y to abciximab
fibrinogen thrombosis
binding
Prevention of
Competitiv platelet
Intravenous,
e, aggregation in Bleeding, less Active
competitive
reversible unstable angina thrombocytopen bleeding,
Tirofiban reversible GP-
GP-2b/3a and MI, ia than hypersensitivit
2b/3a receptor
receptor coronary abciximab y to tirofiban
antagonist
antagonist angioplasty or
stent placement
Prevention of
Competitiv platelet
Intravenous, Active
e, aggregation in Bleeding, less
competitive bleeding,
reversible unstable angina thrombocytopen
Eptifibatide reversible GP- hypersensitivit
GP-2b/3a and MI, ia than
2b/3a receptor y to
receptor coronary abciximab
antagonist eptifibatide
antagonist angioplasty or
stent placement
 Mechanis
Pharmacokinet Contraindicati
Drug Name m of Clinical Uses Side Effects
ics ons
Action
PAR-1
antagonist,
Prevention of
prevents Active
thrombotic Bleeding, no
Oral, long thrombin- bleeding,
Vorapaxar cardiovascular significant side
half-life mediated hypersensitivit
events in MI or effects reported
platelet y to vorapaxar
PAD patients
aggregatio
n
Intravenous, Converts Treatment of Active
activates plasminog thrombi in MI, Bleeding, bleeding,
Alteplase
plasminogen to en to thrombotic arrhythmias recent surgery
plasmin plasmin stroke, PE or trauma
Intravenous, Converts Treatment of Active
activates plasminog thrombi in MI, Bleeding, bleeding,
Reteplase
plasminogen to en to thrombotic arrhythmias recent surgery
plasmin plasmin stroke, PE or trauma
Intravenous, Converts Treatment of Active
Tenecteplas activates plasminog thrombi in MI, Bleeding, bleeding,
e plasminogen to en to thrombotic arrhythmias recent surgery
plasmin plasmin stroke, PE or trauma
Forms an
activator
complex Adjunct to
Hypersensitivit Active
Intravenous, with anticoagulants
y reactions, bleeding,
Streptokina activates plasminog in venous
fatal hypersensitivit
se plasminogen to en to thromboembolis
anaphylactic y to
plasmin convert m, used in MI,
shock streptokinase
plasminog stroke
en to
plasmin
Forms an Adjunct to
Intravenous, Hypersensitivit Active
Anistreplas activator anticoagulants
forms an y reactions, bleeding,
e complex in venous
activator fatal hypersensitivit
with thromboembolis
 Mechanis
Pharmacokinet Contraindicati
Drug Name m of Clinical Uses Side Effects
ics ons
Action
complex with plasminog m, used in MI, anaphylactic y to
plasminogen en to stroke shock streptokinase
convert
plasminog
en to
plasmin
Inhibits
fibrinolysi To stop Active
Oral or s by bleeding caused bleeding,
Thrombosis,
Aminocapr intravenous, occupying by thrombolytic hypersensitivit
hypotension,
oic Acid excreted by lysine drugs and in y to
arrhythmias
kidneys binding hemophilia or aminocaproic
sites on surgery acid
plasmin
Inhibits
fibrinolysi To prevent Active
Thrombosis,
Oral or s by bleeding in bleeding,
especially in
Tranexamic intravenous, occupying hemophilia, hypersensitivit
women who
Acid excreted by lysine stop cyclic y to
smoke or are
kidneys binding heavy menstrual tranexamic
obese
sites on bleeding acid
plasmin

This table integrates both the pharmacokinetics and clinical characteristics of each drug.
Let me know if you'd like further adjustments or additional information!